Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2005

01-03-2005 | Commentary

Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis

Author: Paul G Green

Published in: Arthritis Research & Therapy | Issue 3/2005

Login to get access

Abstract

Many studies have shown that modulation of cytokine function is effective in ameliorating symptoms of rheumatoid arthritis. Neuropeptides have recently been shown to have powerful effects on the production and release of cytokines and have also been shown to exert potent proinflammatory and anti-inflammatory effects in animal models of inflammatory diseases. An analysis of cytokine and neuropeptide content of synovial fluid from patients with rheumatoid arthritis has revealed a significant correlation between two neuropeptides, bombesin/gastrin-releasing peptide and substance P, and the proinflammatory cytokine interleukin-6 as well as the erythrocyte sedimentation rate. These findings provide further evidence for a role of neuropeptides and cytokines in the pathophysiology of rheumatoid arthritis, as well as suggesting additional approaches for the development of novel therapeutic interventions.
Literature
1.
go back to reference Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S: Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R416-R426. 10.1186/ar1503.PubMedCentralCrossRefPubMed Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S: Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R416-R426. 10.1186/ar1503.PubMedCentralCrossRefPubMed
2.
go back to reference Eskandari F, Webster JI, Sternberg EM: Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther. 2003, 5: 251-265. 10.1186/ar1002.PubMedCentralCrossRefPubMed Eskandari F, Webster JI, Sternberg EM: Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther. 2003, 5: 251-265. 10.1186/ar1002.PubMedCentralCrossRefPubMed
3.
go back to reference Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 2001, 44: 493-507. 10.1002/1529-0131(200103)44:3<493::AID-ANR95>3.0.CO;2-U.CrossRefPubMed Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 2001, 44: 493-507. 10.1002/1529-0131(200103)44:3<493::AID-ANR95>3.0.CO;2-U.CrossRefPubMed
4.
go back to reference Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA: Hypothesis: the nervous system may contribute to the patho-physiology of rheumatoid arthritis. J Rheumatol. 1985, 12: 406-411.PubMed Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA: Hypothesis: the nervous system may contribute to the patho-physiology of rheumatoid arthritis. J Rheumatol. 1985, 12: 406-411.PubMed
5.
go back to reference Mapp PI, Kidd BL, Gibson SJ, Terry JM, Revell PA, Ibrahim NB, Blake DR, Polak JM: Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience. 1990, 37: 143-153. 10.1016/0306-4522(90)90199-E.CrossRefPubMed Mapp PI, Kidd BL, Gibson SJ, Terry JM, Revell PA, Ibrahim NB, Blake DR, Polak JM: Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience. 1990, 37: 143-153. 10.1016/0306-4522(90)90199-E.CrossRefPubMed
6.
go back to reference Grigg P: Properties of sensory neurons innervating synovial joints. Cells Tissues Organs. 2001, 169: 218-225. 10.1159/000047885.CrossRefPubMed Grigg P: Properties of sensory neurons innervating synovial joints. Cells Tissues Organs. 2001, 169: 218-225. 10.1159/000047885.CrossRefPubMed
7.
go back to reference Miller LE, Justen HP, Scholmerich J, Straub RH: The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepi-nephrine release from synovial macrophages. FASEB J. 2000, 14: 2097-2107. 10.1096/fj.99-1082com.CrossRefPubMed Miller LE, Justen HP, Scholmerich J, Straub RH: The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepi-nephrine release from synovial macrophages. FASEB J. 2000, 14: 2097-2107. 10.1096/fj.99-1082com.CrossRefPubMed
8.
go back to reference Niissalo S, Hukkanen M, Imai S, Tornwall J, Konttinen YT: Neu-ropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci. 2002, 966: 384-399.CrossRefPubMed Niissalo S, Hukkanen M, Imai S, Tornwall J, Konttinen YT: Neu-ropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci. 2002, 966: 384-399.CrossRefPubMed
9.
go back to reference Cerinic MM, Konttinen Y, Generini S, Cutolo M: Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol. 1998, 10: 220-235.CrossRefPubMed Cerinic MM, Konttinen Y, Generini S, Cutolo M: Neuropeptides and steroid hormones in arthritis. Curr Opin Rheumatol. 1998, 10: 220-235.CrossRefPubMed
10.
11.
go back to reference Mariette X: Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine. 2004, 71: 470-474. 10.1016/j.jbspin.2004.07.008.CrossRefPubMed Mariette X: Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine. 2004, 71: 470-474. 10.1016/j.jbspin.2004.07.008.CrossRefPubMed
12.
go back to reference McInnes IB, Gracie JA: Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. Curr Rheumatol Rep. 2004, 6: 336-342.CrossRefPubMed McInnes IB, Gracie JA: Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. Curr Rheumatol Rep. 2004, 6: 336-342.CrossRefPubMed
13.
go back to reference Roberts LJ: New drugs for rheumatoid arthritis. N Engl J Med. 2004, 351: 2659-2661. 10.1056/NEJM200412163512522.CrossRefPubMed Roberts LJ: New drugs for rheumatoid arthritis. N Engl J Med. 2004, 351: 2659-2661. 10.1056/NEJM200412163512522.CrossRefPubMed
14.
go back to reference Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004, 363: 675-681. 10.1016/S0140-6736(04)15640-7.CrossRefPubMed Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004, 363: 675-681. 10.1016/S0140-6736(04)15640-7.CrossRefPubMed
15.
go back to reference O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F: The role of substance P in inflammatory disease. J Cell Physiol. 2004, 201: 167-180. 10.1002/jcp.20061.CrossRefPubMed O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F: The role of substance P in inflammatory disease. J Cell Physiol. 2004, 201: 167-180. 10.1002/jcp.20061.CrossRefPubMed
16.
go back to reference Bedoui S, Miyake S, Straub RH, von Horsten S, Yamamura T: More sympathy for autoimmunity with neuropeptide Y?. Trends Immunol. 2004, 25: 508-512. 10.1016/j.it.2004.08.005.CrossRefPubMed Bedoui S, Miyake S, Straub RH, von Horsten S, Yamamura T: More sympathy for autoimmunity with neuropeptide Y?. Trends Immunol. 2004, 25: 508-512. 10.1016/j.it.2004.08.005.CrossRefPubMed
17.
go back to reference Keeble JE, Brain SD: A role for substance P in arthritis?. Neurosci Lett. 2004, 361: 176-179. 10.1016/j.neulet.2003.12.020.CrossRefPubMed Keeble JE, Brain SD: A role for substance P in arthritis?. Neurosci Lett. 2004, 361: 176-179. 10.1016/j.neulet.2003.12.020.CrossRefPubMed
18.
go back to reference Baerwald CG, Burmester GR, Krause A: Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis. Rheum Dis Clin North Am. 2000, 26: 841-857.CrossRefPubMed Baerwald CG, Burmester GR, Krause A: Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis. Rheum Dis Clin North Am. 2000, 26: 841-857.CrossRefPubMed
19.
go back to reference Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S: Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol. 2001, 19: 715-720.PubMed Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S: Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol. 2001, 19: 715-720.PubMed
20.
go back to reference Cuesta MC, Quintero L, Pons H, Suarez-Roca H: Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem Int. 2002, 40: 301-306. 10.1016/S0197-0186(01)00094-8.CrossRefPubMed Cuesta MC, Quintero L, Pons H, Suarez-Roca H: Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem Int. 2002, 40: 301-306. 10.1016/S0197-0186(01)00094-8.CrossRefPubMed
21.
go back to reference Delgado M, Pozo D, Ganea D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004, 56: 249-290. 10.1124/pr.56.2.7.CrossRefPubMed Delgado M, Pozo D, Ganea D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004, 56: 249-290. 10.1124/pr.56.2.7.CrossRefPubMed
Metadata
Title
Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis
Author
Paul G Green
Publication date
01-03-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1746

Other articles of this Issue 3/2005

Arthritis Research & Therapy 3/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.